Coenzyme M

Generic Name: Coenzyme M

Brand Names: Uromitexan

Drug Type: Small Molecule

Chemical Formula: C_₂H_₆O_₃S_₂

CAS Number: 3375-50-6

Unique Ingredient Identifier: VHD28S0H7F

Background: Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.

Indication: Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.

Associated Conditions: Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide

Clinical Trials

Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma

Phase 2

Active, not recruiting

Conditions: Retinoblastoma

Interventions: Drug: vincristine
Drug: topotecan
Drug: filgrastim
Drug: PEG-filgrastim
Drug: carboplatin
Drug: cyclophosphamide
Other: focal therapy
Drug: etoposide
Drug: MESNA
Drug: doxorubicin
Procedure: enucleation
Radiation: external beam radiation or proton beam radiation

First Posted Date: 2013-02-05

Last Posted Date: 2024-04-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 174

Registration Number: NCT01783535

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients

Phase 2

Conditions: Non-small Cell Lung Cancer
Effects of Chemotherapy

Interventions: Drug: Gefitinib group
Drug: Vinorelbine, Ifosfamide, Mesna

First Posted Date: 2012-12-13

Last Posted Date: 2012-12-13

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 120

Registration Number: NCT01749072

Locations: 🇨🇳
Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing, Beijing, China

Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma

Phase 4

Completed

Conditions: Multiple Myeloma

Interventions: Procedure: Autologous peripheral blood stem cell transplant
Drug: Lenalidomide
Procedure: Stem cell collection
Drug: Dexamethasone
Drug: Melphalan
Drug: G-CSF
Drug: Cyclophosphamide
Drug: Mesna

First Posted Date: 2012-11-22

Last Posted Date: 2020-02-05

Lead Sponsor: Columbia University

Target Recruit Count: 60

Registration Number: NCT01731886

Locations: 🇺🇸
Columbia University, New York, New York, United States

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Phase 2

Withdrawn

Conditions: Blastic Phase Chronic Myelogenous Leukemia
Untreated Adult Acute Lymphoblastic Leukemia
B-cell Adult Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions: Drug: nilotinib
Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: methotrexate
Drug: cytarabine
Drug: prednisone
Drug: mesna
Drug: dexamethasone
Drug: leucovorin calcium

First Posted Date: 2012-08-21

Last Posted Date: 2015-10-30

Lead Sponsor: Mayo Clinic

Registration Number: NCT01670084

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Not Applicable

Recruiting

Conditions: Omenn's Syndrome
Wiskott-Aldrich Syndrome
Bare Lymphocyte Syndrome
SCID
Hemophagocytic Lymphohistiocytosis
Langerhan's Cell Histiocytosis
Reticular Dysgenesis
Common Variable Immunodeficiency
Hyper IgM Syndrome
Griscelli Syndrome

Interventions: Drug: Alemtuzumab 0.3 mg
Drug: Cyclophosphamide
Drug: Melphalan
Drug: Alemtuzumab 0.2 mg
Drug: Fludarabine phosphate 40 mg
Drug: Busulfan
Drug: Fludarabine phosphate 30 mg
Biological: Stem Cell Transplantation
Drug: MESNA

First Posted Date: 2012-07-27

Last Posted Date: 2025-02-03

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 30

Registration Number: NCT01652092

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Not Applicable

Completed

Conditions: Ewing's Family Tumors
Renal Tumors
Hepatoblastoma
Rhabdomyosarcoma
Soft Tissue Sarcoma
Primary Malignant Brain Neoplasms
Retinoblastoma
Medulloblastoma
Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)
Atypical Teratoid/Rhabdoid Tumor (AT/RT)

Interventions: Drug: Ifosfamide
Drug: Etoposide
Drug: Mesna
Biological: G-CSF
Drug: Anti-seizure prophylaxis
Drug: Busulfan
Drug: Melphalan
Drug: Ursodiol
Drug: Paclitaxel
Drug: Thiotepa
Drug: Carboplatin
Biological: Autologous stem cell infusion
Procedure: Leukapheresis
Radiation: Radiation

First Posted Date: 2012-01-06

Last Posted Date: 2024-02-26

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 44

Registration Number: NCT01505569

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

Not Applicable

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting
Effects of Chemotherapy
Sarcoma
Adverse Effects of Medical Drugs

Interventions: Drug: Fosaprepitant
Drug: Dexamethasone
Drug: 5HT3 receptor antagonist
Drug: Ifosfamide-based chemotherapy (AI)
Drug: Doxorubicin
Drug: Mesna
Drug: Ifosfamide
Drug: Vincristine

First Posted Date: 2011-12-12

Last Posted Date: 2016-04-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 47

Registration Number: NCT01490060

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients

Phase 2

Completed

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Ofatumumab
Drug: Etoposide
Drug: Ifosfamid
Drug: Mesna
Drug: Cytarabine
Drug: Methotrexate
Drug: Leukovorin
Drug: Granulocyte-Colony Stimulating Factor

First Posted Date: 2011-11-29

Last Posted Date: 2021-12-27

Lead Sponsor: Polish Lymphoma Research Group

Target Recruit Count: 77

Registration Number: NCT01481272

Locations: 🇵🇱
Instytut Hematologii i Transfuzjologii, Warszawa, Mazowieckie, Poland
🇵🇱
Dolnośląskie Centrum Transplantacji Komórkowych, Wrocław, Dolnośląskie, Poland
🇵🇱
Uniwersyteckie Cenrum Medyczne, Gdańsk, Pomorskie, Poland

and more 5 locations

Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial

Phase 3

Terminated

Conditions: Scleroderma, Systemic

Interventions: Biological: Peripheral Blood Stem Cells
Drug: Cyclophosphamide
Drug: Mesna
Drug: rATG
Drug: Methylprednisolone
Drug: Filgrastim
Drug: Fludarabine

First Posted Date: 2011-10-04

Last Posted Date: 2020-07-23

Lead Sponsor: Northwestern University

Target Recruit Count: 44

Registration Number: NCT01445821

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia

Early Phase 1

Completed

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions: Drug: G-CSF
Drug: Ifosfamide
Drug: Etoposide
Drug: Dexamethasone
Drug: Mesna

First Posted Date: 2011-04-08

Last Posted Date: 2016-09-20

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 13

Registration Number: NCT01331590

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy